Suivi immunologique des patients traités par cellules CAR-T pour hémopathie maligne: recommandations du groupe CARTi et de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Article Article scientifique Article Suivi immunologique des patients traités par cellules CAR-T pour hémopathie maligne: recommandations du groupe CARTi et de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) fre [Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)] 2021-07-09 2021-12 author Rubio Marie Thérèse author Varlet Pauline author Allain Vincent author Ballot Caroline author Cuffel Alexis author Deschamps Marina author Ferrand Christophe author Foguenne Jacques author Forcade Edouard author Huynh Anne author Guihot Amélie author Latouche Jean-Baptiste author Lemarie Claude author Martinroche Guillaume author Morin Florence 818087 author Nguyen Van Sang Stéphanie 524084 author Schmit Kathleen author Servais Sophie author Simonetta Federico 936876 author Yakoub-Agha Ibrahim author Caillat Zucman Sophie S53-S64 10.1016/j.bulcan.2021.04.008 34253335 0007-4551 CAR-T cells represent a new anti-tumor immunotherapy which has shown its clinical efficacy in B-cell malignancies. The results of clinical trials carried out in this context have shown that certain immunological characteristics of patients before (at the time of apheresis) and after the administration of the treatment, or of the CAR-T cells themselves, are correlated with the response to the treatment or to its toxicity. However, to date, there are no recommendations on the immunological monitoring of patients treated in real life. The objectives of this workshop were to determine, based on data from the literature and the experience of the centers, the immunological analyses to be carried out in patients treated with CAR-T cells. The recommendations relate to the characterization of the patient's immune cells at the time of apheresis, the characterization of the injected CAR-T cells, as well as the monitoring of the CAR-T cells and other parameters of immune reconstitution in the patient after administration of the treatment. Harmonization of practices will allow clinical-biological correlation studies to be carried out in patients treated in real life with the aim of identifying factors predictive of response and toxicity. Such data could have a major medico-economic impact by making it possible to identify the patients who will optimally benefit from these expensive treatments. Biomarker Biomarqueurs CAR-T cells Cellules CAR-T Immune monitoring Prediction Prédiction Recommandations Recommendations Suivi immunologique Bacterial Infections / etiology Blood Component Removal Cytokine Release Syndrome / immunology Flow Cytometry Hematologic Neoplasms / immunology Hematologic Neoplasms / therapy Humans Immune Reconstitution Immunity, Cellular Immunotherapy, Adoptive / adverse effects Leukemia, Lymphocytic, Chronic, B-Cell / immunology Leukemia, Lymphocytic, Chronic, B-Cell / therapy Lymphocyte Depletion Lymphoma, Large B-Cell, Diffuse / immunology Lymphoma, Large B-Cell, Diffuse / therapy Monitoring, Immunologic / methods Monitoring, Immunologic / standards Multiple Myeloma / immunology Multiple Myeloma / therapy Mycoses / etiology Neurotoxicity Syndromes / immunology Polymerase Chain Reaction Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy Recurrence Societies, Medical T-Lymphocytes / drug effects T-Lymphocytes / transplantation Virus Diseases / etiology Dewey 616 56 Département de médecine 221 false 1216 Leucémie et transplantation allogénique de cellules souches hématopoïétiques 982 Bulletin du cancer 108 12S 20cacbc0-bdac-463b-a62c-794920b2ea10 Article (Published version) Public 1-s2.0-S0007455121002058-main.pdf 1930982 application/pdf openAccess Faculté de médecine / Section de médecine clinique / Département de médecine

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Suivi immunologique des patients traités par cellules CAR-T pour hémopathie maligne: recommandations du groupe CARTi et de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)	Bulletin du cancer			2021	240	437

Archive ouverte UNIGE

Morin, Florence